WallStSmart
KTTA

Pasithea Therapeutics Corp

NASDAQ: KTTA · HEALTHCARE · BIOTECHNOLOGY

$0.69
+0.87% today

Updated 2026-04-30

Market cap
$17.21M
P/E ratio
P/S ratio
42.15x
EPS (TTM)
$-2.91
Dividend yield
52W range
$0 – $2
Volume
0.4M

WallStSmart proprietary scores

40
out of 100
Grade: D
Sell
Investment rating
6.3
Growth
B
5.3
Quality
C+
3.0
Profitability
D
5.0
Valuation
C+
3/9
Piotroski F-Score
Weak
-1.2
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target
$3.00
+331.84%
12-Month target
Intrinsic (DCF)
Margin of safety
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths
+ Revenue growth 1,498.00% QoQ
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -1.22 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-5.40M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$486559.00$486559.00$0.00$0.00$486560.00
Net income$-13.94M$-15.96M$-13.90M$-20.43M$-10.11M
EPS$-2.91
Free cash flow$-13.80M$-13.46M$-13.92M$-15.21B$-5.40M
Profit margin-2,864.29%-3,280.52%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
KTTA$17.21M406.33.05.05.3Hold
LLY$760.43B7810.010.05.06.5Strong Buy
JNJ$547.28B594.79.03.36.0-43.54%Buy
ABBV$360.63B634.08.04.75.0-29.31%Buy
UNH$322.34B545.35.57.34.8+42.06%Buy
AZN$294.17B646.78.05.35.0+4.07%Buy

Smart narrative

Pasithea Therapeutics Corp trades at $0.69. Our Smart Value Score of 40/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -1.22, it sits in the distress. TTM revenue stands at $486560.00.

Frequently asked questions

What is Pasithea Therapeutics Corp's stock price?
Pasithea Therapeutics Corp (KTTA) trades at $0.69.
Is Pasithea Therapeutics Corp overvalued?
Smart Value Score 40/100 (Grade D, Sell).
What is the price target of Pasithea Therapeutics Corp (KTTA)?
The analyst target price is $3.00, representing +331.8% upside from the current price of $0.69.
What is Pasithea Therapeutics Corp's revenue?
TTM revenue is $486560.00.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
-1.22 — distress.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio42.15x
ROE-58.40%
Beta0.25
50D MA$0.77
200D MA$0.81
Shares out0.02B
Float0.01B
Short ratio
Avg volume0.4M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years